닫기

Ex) Article Title, Author, Keywords

Education Series

Split Viewer

Journal of Digestive Cancer Research 2024; 12(3): 234-236

Published online December 20, 2024

https://doi.org/10.52927/jdcr.2024.12.3.234

© Korean Society of Gastrointestinal Cancer Research

Adjuvant Treatment Required during Survivorship Following Surgery and Chemotherapy for Colorectal Cancer


Jong Yoon Lee



Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea

Correspondence to :
Jong Yoon Lee, E-mail: ljyhateo@gmail.com, https://orcid.org/0000-0002-6542-8062

Received: November 18, 2024; Revised: December 11, 2024; Accepted: December 11, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0). which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

QUESTION: A 65-year-old man diagnosed with stage III sigmoid colon cancer underwent low anterior resection followed by six months of adjuvant chemotherapy. He is currently attending regular follow-ups with no signs of recurrence on surveillance examinations. However, the patient complains of loose stools and tingling sensations in his hands and feet. What advice can be provided regarding appropriate management of these symptoms and the necessary care for cancer survivors?

ANSWER: Antidiarrheal medications like loperamide and calcium polycarbophil can be effective. Duloxetine is currently the most evidence-based first-line treatment for chemotherapy induced peripheral neuropathy.

REVIEW: By 2030, the global incidence of colorectal cancer (CRC) is expected to increase by 60%, reaching 2.2 million cases annually [1]. With successful treatments improving the 5-year survival rate to 65%, the management and care of CRC survivors have become a critical challenge for healthcare providers [2]. Cancer survivorship entails essential care aimed at managing treatment-related symptoms and complications, preventing recurrence, and monitoring for new cancers.

Nearly half of CRC survivors experience chronic diarrhea [3]. Patients undergoing low anterior resection for rectal cancer or resection and anastomosis of the lower gastrointestinal tract often report increased bowel frequency, incontinence, perianal irritation, and incomplete evacuation. Similarly, resection of the ascending colon can lead to loose stools due to the loss of water and electrolyte absorption. It should be noted that these symptoms may improve over time as part of the adaptation process after surgery, but in some cases, medication may be helpful [4,5]. Antidiarrheal medications like loperamide and calcium polycarbophil can be effective [3]. For radiation proctitis-induced diarrhea, loperamide or diphenoxylate/atropine serves as first-line treatment [3]. Dietary modifications, such as avoiding raw vegetables and adopting a low-fat or elemental diet, can also help [5].

Chemotherapy-induced neuropathy, particularly from oxaliplatin used in FOLFOX or CAPEOX regimens, is a significant concern for CRC survivors. This condition can manifest as various sensory symptoms, including numbness, tingling, a pins-and-needles sensation, heightened sensitivity to touch, and even severe pain from light contact. In some cases, patients may experience a complete loss of sensation in the affected areas. While neuropathy often improves over time, symptom management is crucial. Duloxetine is currently the most evidence-based first-line treatment [6]. Other options, such as tricyclic antidepressants, gabapentin, pregabalin, baclofen, amitriptyline, and compounded topical gels, may provide some relief. However, treatments like vitamins, acetyl-L-carnitine, or acupuncture lack sufficient evidence and are not recommended [7].

Cancer survivors, including those with CRC, face a range of issues that require comprehensive monitoring beyond the primary disease. Adjuvant treatments such as chemotherapy and radiation therapy can contribute to various long-term complications. Though cardiovascular morbidity does not show a marked increase among long-term CRC survivors, attention to cardiovascular health is crucial. Adjuvant chemotherapy for CRC is not highly associated with acute or chronic cardiotoxicity but may exert some effects Obesity and sedentary lifestyles are linked to increased CRC risk and may accelerate cardiovascular disease progression in CRC survivors. Thus, lifestyle modifications are imperative for these patients [8].

Patients with persistent urinary retention or dysfunction after CRC surgery should be referred to a urologist. Symptoms such as incontinence, frequent or urgent urination, dysuria, and hematuria may develop after pelvic radiation therapy, though evidence for effective treatment remains insufficient [9]. Additionally, CRC survivors may face mental health issues, cognitive impairments, or sexual dysfunction, which require specialist referrals and tailored care [10].

To reduce the risk of recurrence after CRC survival, several lifestyle modifications are recommended. First, increased physical activity has been shown to lower the risk of CRC by 20 to 30%. Exercise not only aids in preventing obesity but also promotes intestinal motility, which can improve gastrointestinal function after colorectal surgery. Specifically, engaging in moderate-intensity exercise that induces sweating, such as 30 minutes of activity 3 to 5 times per week, is beneficial [11]. In addition to exercise, other lifestyle changes are critical. Limiting alcohol consumption is important, as even moderate intake (e.g., 10 g of alcohol per day) has been associated with a 9% increase in CRC risk [12]. Maintaining a healthy weight and avoiding unhealthy dietary choices, such as animal fats and processed meats, further contribute to reducing recurrence risk and supporting overall health [13].

In conclusion, with increasing survival rates, supportive care during CRC survivorship is essential. Comprehensive, high-quality, and multidisciplinary support across all areas of survivorship care is necessary to optimize health outcomes and quality of life for CRC survivors.

No potential conflict of interest relevant to this article was reported.

  1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683-691. https://doi.org/10.1136/gutjnl-2015-310912.
    Pubmed CrossRef
  2. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020;70:145-164. https://doi.org/10.3322/caac.21601.
    Pubmed CrossRef
  3. El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin 2015;65:428-455. https://doi.org/10.3322/caac.21286.
    Pubmed KoreaMed CrossRef
  4. Al Rashid F, Liberman AS, Charlebois P, et al. The impact of bowel dysfunction on health-related quality of life after rectal cancer surgery: a systematic review. Tech Coloproctol 2022;26:515-527. https://doi.org/10.1007/s10151-022-02594-0.
    Pubmed CrossRef
  5. Yde J, Larsen HM, Laurberg S, Krogh K, Moeller HB. Chronic diarrhoea following surgery for colon cancer-frequency, causes and treatment options. Int J Colorectal Dis 2018;33:683-694. https://doi.org/10.1007/s00384-018-2993-y.
    Pubmed CrossRef
  6. Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am J Health Syst Pharm 2014;71:19-25. https://doi.org/10.2146/ajhp130126.
    Pubmed CrossRef
  7. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 2020;38:3325-3348. https://doi.org/10.1200/jco.20.01399.
    Pubmed CrossRef
  8. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014;15:47. https://doi.org/10.1186/2050-6511-15-47.
    Pubmed KoreaMed CrossRef
  9. Lange MM, Maas CP, Marijnen CA, et al. ; Cooperative Clinical Investigators of the Dutch Total Mesorectal Excision Trial. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg 2008;95:1020-1028. https://doi.org/10.1002/bjs.6126.
    Pubmed CrossRef
  10. Averyt JC, Nishimoto PW. Psychosocial issues in colorectal cancer survivorship: the top ten questions patients may not be asking. J Gastrointest Oncol 2014;5:395-400. https://doi.org/10.3978/j.issn.2078-6891.2014.058.
  11. Amirsasan R, Akbarzadeh M, Akbarzadeh S. Exercise and colorectal cancer: prevention and molecular mechanisms. Cancer Cell Int 2022;22:247. https://doi.org/10.1186/s12935-022-02670-3.
    Pubmed KoreaMed CrossRef
  12. Park SY, Wilkens LR, Setiawan VW, Monroe KR, Haiman CA, Le Marchand L. Alcohol intake and colorectal cancer risk in the multiethnic cohort study. Am J Epidemiol 2019;188:67-76. https://doi.org/10.1093/aje/kwy208.
    Pubmed KoreaMed CrossRef
  13. Mehta M, Shike M. Diet and physical activity in the prevention of colorectal cancer. J Natl Compr Canc Netw 2014;12:1721-1726. https://doi.org/10.6004/jnccn.2014.0174.
    Pubmed CrossRef

Article

Education Series

Journal of Digestive Cancer Research 2024; 12(3): 234-236

Published online December 20, 2024 https://doi.org/10.52927/jdcr.2024.12.3.234

Copyright © Korean Society of Gastrointestinal Cancer Research.

Adjuvant Treatment Required during Survivorship Following Surgery and Chemotherapy for Colorectal Cancer

Jong Yoon Lee

Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea

Correspondence to:Jong Yoon Lee, E-mail: ljyhateo@gmail.com, https://orcid.org/0000-0002-6542-8062

Received: November 18, 2024; Revised: December 11, 2024; Accepted: December 11, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0). which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Body

QUESTION: A 65-year-old man diagnosed with stage III sigmoid colon cancer underwent low anterior resection followed by six months of adjuvant chemotherapy. He is currently attending regular follow-ups with no signs of recurrence on surveillance examinations. However, the patient complains of loose stools and tingling sensations in his hands and feet. What advice can be provided regarding appropriate management of these symptoms and the necessary care for cancer survivors?

ANSWER: Antidiarrheal medications like loperamide and calcium polycarbophil can be effective. Duloxetine is currently the most evidence-based first-line treatment for chemotherapy induced peripheral neuropathy.

REVIEW: By 2030, the global incidence of colorectal cancer (CRC) is expected to increase by 60%, reaching 2.2 million cases annually [1]. With successful treatments improving the 5-year survival rate to 65%, the management and care of CRC survivors have become a critical challenge for healthcare providers [2]. Cancer survivorship entails essential care aimed at managing treatment-related symptoms and complications, preventing recurrence, and monitoring for new cancers.

Nearly half of CRC survivors experience chronic diarrhea [3]. Patients undergoing low anterior resection for rectal cancer or resection and anastomosis of the lower gastrointestinal tract often report increased bowel frequency, incontinence, perianal irritation, and incomplete evacuation. Similarly, resection of the ascending colon can lead to loose stools due to the loss of water and electrolyte absorption. It should be noted that these symptoms may improve over time as part of the adaptation process after surgery, but in some cases, medication may be helpful [4,5]. Antidiarrheal medications like loperamide and calcium polycarbophil can be effective [3]. For radiation proctitis-induced diarrhea, loperamide or diphenoxylate/atropine serves as first-line treatment [3]. Dietary modifications, such as avoiding raw vegetables and adopting a low-fat or elemental diet, can also help [5].

Chemotherapy-induced neuropathy, particularly from oxaliplatin used in FOLFOX or CAPEOX regimens, is a significant concern for CRC survivors. This condition can manifest as various sensory symptoms, including numbness, tingling, a pins-and-needles sensation, heightened sensitivity to touch, and even severe pain from light contact. In some cases, patients may experience a complete loss of sensation in the affected areas. While neuropathy often improves over time, symptom management is crucial. Duloxetine is currently the most evidence-based first-line treatment [6]. Other options, such as tricyclic antidepressants, gabapentin, pregabalin, baclofen, amitriptyline, and compounded topical gels, may provide some relief. However, treatments like vitamins, acetyl-L-carnitine, or acupuncture lack sufficient evidence and are not recommended [7].

Cancer survivors, including those with CRC, face a range of issues that require comprehensive monitoring beyond the primary disease. Adjuvant treatments such as chemotherapy and radiation therapy can contribute to various long-term complications. Though cardiovascular morbidity does not show a marked increase among long-term CRC survivors, attention to cardiovascular health is crucial. Adjuvant chemotherapy for CRC is not highly associated with acute or chronic cardiotoxicity but may exert some effects Obesity and sedentary lifestyles are linked to increased CRC risk and may accelerate cardiovascular disease progression in CRC survivors. Thus, lifestyle modifications are imperative for these patients [8].

Patients with persistent urinary retention or dysfunction after CRC surgery should be referred to a urologist. Symptoms such as incontinence, frequent or urgent urination, dysuria, and hematuria may develop after pelvic radiation therapy, though evidence for effective treatment remains insufficient [9]. Additionally, CRC survivors may face mental health issues, cognitive impairments, or sexual dysfunction, which require specialist referrals and tailored care [10].

To reduce the risk of recurrence after CRC survival, several lifestyle modifications are recommended. First, increased physical activity has been shown to lower the risk of CRC by 20 to 30%. Exercise not only aids in preventing obesity but also promotes intestinal motility, which can improve gastrointestinal function after colorectal surgery. Specifically, engaging in moderate-intensity exercise that induces sweating, such as 30 minutes of activity 3 to 5 times per week, is beneficial [11]. In addition to exercise, other lifestyle changes are critical. Limiting alcohol consumption is important, as even moderate intake (e.g., 10 g of alcohol per day) has been associated with a 9% increase in CRC risk [12]. Maintaining a healthy weight and avoiding unhealthy dietary choices, such as animal fats and processed meats, further contribute to reducing recurrence risk and supporting overall health [13].

In conclusion, with increasing survival rates, supportive care during CRC survivorship is essential. Comprehensive, high-quality, and multidisciplinary support across all areas of survivorship care is necessary to optimize health outcomes and quality of life for CRC survivors.

FUNDING

None.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

References

  1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683-691. https://doi.org/10.1136/gutjnl-2015-310912.
    Pubmed CrossRef
  2. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020;70:145-164. https://doi.org/10.3322/caac.21601.
    Pubmed CrossRef
  3. El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin 2015;65:428-455. https://doi.org/10.3322/caac.21286.
    Pubmed KoreaMed CrossRef
  4. Al Rashid F, Liberman AS, Charlebois P, et al. The impact of bowel dysfunction on health-related quality of life after rectal cancer surgery: a systematic review. Tech Coloproctol 2022;26:515-527. https://doi.org/10.1007/s10151-022-02594-0.
    Pubmed CrossRef
  5. Yde J, Larsen HM, Laurberg S, Krogh K, Moeller HB. Chronic diarrhoea following surgery for colon cancer-frequency, causes and treatment options. Int J Colorectal Dis 2018;33:683-694. https://doi.org/10.1007/s00384-018-2993-y.
    Pubmed CrossRef
  6. Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am J Health Syst Pharm 2014;71:19-25. https://doi.org/10.2146/ajhp130126.
    Pubmed CrossRef
  7. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 2020;38:3325-3348. https://doi.org/10.1200/jco.20.01399.
    Pubmed CrossRef
  8. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014;15:47. https://doi.org/10.1186/2050-6511-15-47.
    Pubmed KoreaMed CrossRef
  9. Lange MM, Maas CP, Marijnen CA, et al. ; Cooperative Clinical Investigators of the Dutch Total Mesorectal Excision Trial. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg 2008;95:1020-1028. https://doi.org/10.1002/bjs.6126.
    Pubmed CrossRef
  10. Averyt JC, Nishimoto PW. Psychosocial issues in colorectal cancer survivorship: the top ten questions patients may not be asking. J Gastrointest Oncol 2014;5:395-400. https://doi.org/10.3978/j.issn.2078-6891.2014.058.
  11. Amirsasan R, Akbarzadeh M, Akbarzadeh S. Exercise and colorectal cancer: prevention and molecular mechanisms. Cancer Cell Int 2022;22:247. https://doi.org/10.1186/s12935-022-02670-3.
    Pubmed KoreaMed CrossRef
  12. Park SY, Wilkens LR, Setiawan VW, Monroe KR, Haiman CA, Le Marchand L. Alcohol intake and colorectal cancer risk in the multiethnic cohort study. Am J Epidemiol 2019;188:67-76. https://doi.org/10.1093/aje/kwy208.
    Pubmed KoreaMed CrossRef
  13. Mehta M, Shike M. Diet and physical activity in the prevention of colorectal cancer. J Natl Compr Canc Netw 2014;12:1721-1726. https://doi.org/10.6004/jnccn.2014.0174.
    Pubmed CrossRef

Journal Info

JDCR
Vol.12 No.3
December 20, 2024
eISSN : 2950-9505
pISSN : 2950-9394
Frequency: Triannual

open access

Article Tools

Stats or Metrics

Share this article on

  • line

Journal of Digestive Cancer Research

eISSN 2950-9505
pISSN 2950-9394

  • 2021
  • 2022
  • 2023
  • 2024
  • 2025